

Global Hepatitis Drugs Market Growth 2025-2031

<https://marketpublishers.com/r/GEA9010DB8D4EN.html>

Date: October 2025

Pages: 105

Price: US\$ 3,660.00 (Single User License)

ID: GEA9010DB8D4EN

Abstracts

The global Hepatitis Drugs market size is predicted to grow from US\$ 126190 million in 2025 to US\$ 474250 million in 2031; it is expected to grow at a CAGR of 24.7% from 2025 to 2031.

The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.

Hepatitis is an inflammatory condition that occurs due to infection by hepatitis virus. It predominantly affects the liver and also causes damage to other body parts such as digestive system and brain. Apart from viral infections, hepatitis can also be caused by toxic substances, alcohol consumption, and autoimmune diseases. The viruses that cause hepatitis are of several types: A, B, C, D, E, and G. The most common type of hepatitis viruses are A, B, and C. Hepatitis viruses can cause either acute or chronic infections.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic

has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

LP Information, Inc. (LPI) ' newest research report, the ?Hepatitis Drugs Industry Forecast? looks at past sales and reviews total world Hepatitis Drugs sales in 2024, providing a comprehensive analysis by region and market sector of projected Hepatitis Drugs sales for 2025 through 2031. With Hepatitis Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Hepatitis Drugs industry.

This Insight Report provides a comprehensive analysis of the global Hepatitis Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Hepatitis Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Hepatitis Drugs market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Hepatitis Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Hepatitis Drugs.

This report presents a comprehensive overview, market shares, and growth opportunities of Hepatitis Drugs market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

VEMLIDY

EPCLUSA

SOVALDI

INCIVEK

OLYSIO

VICTRELIS

VIREAD

HEPSERA

BARACLUDE

TYZEKA

Segmentation by Application:

Hepatitis A

Hepatitis B

Hepatitis C

Hepatitis D

Hepatitis E

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.

F. Hoffmann-La Roche

Gilead Sciences

GlaxoSmithKline

Johnson & Johnson

Merck

Novartis

Vertex Pharmaceuticals

Abbvie

Achillion Pharmaceuticals

Bristol-Myers Squibb

Key Questions Addressed in this Report

What is the 10-year outlook for the global Hepatitis Drugs market?

What factors are driving Hepatitis Drugs market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Hepatitis Drugs market opportunities vary by end market size?

How does Hepatitis Drugs break out by Type, by Application?

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

- 2.1 World Market Overview
 - 2.1.1 Global Hepatitis Drugs Annual Sales 2020-2031
 - 2.1.2 World Current & Future Analysis for Hepatitis Drugs by Geographic Region, 2020, 2024 & 2031
 - 2.1.3 World Current & Future Analysis for Hepatitis Drugs by Country/Region, 2020, 2024 & 2031
- 2.2 Hepatitis Drugs Segment by Type
 - 2.2.1 VEMLIDY
 - 2.2.2 EPCLUSA
 - 2.2.3 SOVALDI
 - 2.2.4 INCIVEK
 - 2.2.5 OLYSIO
 - 2.2.6 VICTRELIS
 - 2.2.7 VIREAD
 - 2.2.8 HEPSERA
 - 2.2.9 BARACLUDE
- 2.3 Hepatitis Drugs Sales by Type
 - 2.3.1 Global Hepatitis Drugs Sales Market Share by Type (2020-2025)
 - 2.3.2 Global Hepatitis Drugs Revenue and Market Share by Type (2020-2025)
 - 2.3.3 Global Hepatitis Drugs Sale Price by Type (2020-2025)
- 2.4 Hepatitis Drugs Segment by Application
 - 2.4.1 Hepatitis A
 - 2.4.2 Hepatitis B
 - 2.4.3 Hepatitis C

2.4.4 Hepatitis D

2.4.5 Hepatitis E

2.5 Hepatitis Drugs Sales by Application

2.5.1 Global Hepatitis Drugs Sale Market Share by Application (2020-2025)

2.5.2 Global Hepatitis Drugs Revenue and Market Share by Application (2020-2025)

2.5.3 Global Hepatitis Drugs Sale Price by Application (2020-2025)

3 GLOBAL BY COMPANY

3.1 Global Hepatitis Drugs Breakdown Data by Company

3.1.1 Global Hepatitis Drugs Annual Sales by Company (2020-2025)

3.1.2 Global Hepatitis Drugs Sales Market Share by Company (2020-2025)

3.2 Global Hepatitis Drugs Annual Revenue by Company (2020-2025)

3.2.1 Global Hepatitis Drugs Revenue by Company (2020-2025)

3.2.2 Global Hepatitis Drugs Revenue Market Share by Company (2020-2025)

3.3 Global Hepatitis Drugs Sale Price by Company

3.4 Key Manufacturers Hepatitis Drugs Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers Hepatitis Drugs Product Location Distribution

3.4.2 Players Hepatitis Drugs Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)

3.6 New Products and Potential Entrants

3.7 Market M&A Activity & Strategy

4 WORLD HISTORIC REVIEW FOR HEPATITIS DRUGS BY GEOGRAPHIC REGION

4.1 World Historic Hepatitis Drugs Market Size by Geographic Region (2020-2025)

4.1.1 Global Hepatitis Drugs Annual Sales by Geographic Region (2020-2025)

4.1.2 Global Hepatitis Drugs Annual Revenue by Geographic Region (2020-2025)

4.2 World Historic Hepatitis Drugs Market Size by Country/Region (2020-2025)

4.2.1 Global Hepatitis Drugs Annual Sales by Country/Region (2020-2025)

4.2.2 Global Hepatitis Drugs Annual Revenue by Country/Region (2020-2025)

4.3 Americas Hepatitis Drugs Sales Growth

4.4 APAC Hepatitis Drugs Sales Growth

4.5 Europe Hepatitis Drugs Sales Growth

4.6 Middle East & Africa Hepatitis Drugs Sales Growth

5 AMERICAS

5.1 Americas Hepatitis Drugs Sales by Country

5.1.1 Americas Hepatitis Drugs Sales by Country (2020-2025)

5.1.2 Americas Hepatitis Drugs Revenue by Country (2020-2025)

5.2 Americas Hepatitis Drugs Sales by Type (2020-2025)

5.3 Americas Hepatitis Drugs Sales by Application (2020-2025)

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC Hepatitis Drugs Sales by Region

6.1.1 APAC Hepatitis Drugs Sales by Region (2020-2025)

6.1.2 APAC Hepatitis Drugs Revenue by Region (2020-2025)

6.2 APAC Hepatitis Drugs Sales by Type (2020-2025)

6.3 APAC Hepatitis Drugs Sales by Application (2020-2025)

6.4 China

6.5 Japan

6.6 South Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

6.10 China Taiwan

7 EUROPE

7.1 Europe Hepatitis Drugs by Country

7.1.1 Europe Hepatitis Drugs Sales by Country (2020-2025)

7.1.2 Europe Hepatitis Drugs Revenue by Country (2020-2025)

7.2 Europe Hepatitis Drugs Sales by Type (2020-2025)

7.3 Europe Hepatitis Drugs Sales by Application (2020-2025)

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Hepatitis Drugs by Country

8.1.1 Middle East & Africa Hepatitis Drugs Sales by Country (2020-2025)

8.1.2 Middle East & Africa Hepatitis Drugs Revenue by Country (2020-2025)

8.2 Middle East & Africa Hepatitis Drugs Sales by Type (2020-2025)

8.3 Middle East & Africa Hepatitis Drugs Sales by Application (2020-2025)

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers

10.2 Manufacturing Cost Structure Analysis of Hepatitis Drugs

10.3 Manufacturing Process Analysis of Hepatitis Drugs

10.4 Industry Chain Structure of Hepatitis Drugs

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel

11.1.1 Direct Channels

11.1.2 Indirect Channels

11.2 Hepatitis Drugs Distributors

11.3 Hepatitis Drugs Customer

12 WORLD FORECAST REVIEW FOR HEPATITIS DRUGS BY GEOGRAPHIC REGION

12.1 Global Hepatitis Drugs Market Size Forecast by Region

- 12.1.1 Global Hepatitis Drugs Forecast by Region (2026-2031)
- 12.1.2 Global Hepatitis Drugs Annual Revenue Forecast by Region (2026-2031)
- 12.2 Americas Forecast by Country (2026-2031)
- 12.3 APAC Forecast by Region (2026-2031)
- 12.4 Europe Forecast by Country (2026-2031)
- 12.5 Middle East & Africa Forecast by Country (2026-2031)
- 12.6 Global Hepatitis Drugs Forecast by Type (2026-2031)
- 12.7 Global Hepatitis Drugs Forecast by Application (2026-2031)

13 KEY PLAYERS ANALYSIS

13.1 F. Hoffmann-La Roche

- 13.1.1 F. Hoffmann-La Roche Company Information
- 13.1.2 F. Hoffmann-La Roche Hepatitis Drugs Product Portfolios and Specifications
- 13.1.3 F. Hoffmann-La Roche Hepatitis Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
- 13.1.4 F. Hoffmann-La Roche Main Business Overview
- 13.1.5 F. Hoffmann-La Roche Latest Developments

13.2 Gilead Sciences

- 13.2.1 Gilead Sciences Company Information
- 13.2.2 Gilead Sciences Hepatitis Drugs Product Portfolios and Specifications
- 13.2.3 Gilead Sciences Hepatitis Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
- 13.2.4 Gilead Sciences Main Business Overview
- 13.2.5 Gilead Sciences Latest Developments

13.3 GlaxoSmithKline

- 13.3.1 GlaxoSmithKline Company Information
- 13.3.2 GlaxoSmithKline Hepatitis Drugs Product Portfolios and Specifications
- 13.3.3 GlaxoSmithKline Hepatitis Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
- 13.3.4 GlaxoSmithKline Main Business Overview
- 13.3.5 GlaxoSmithKline Latest Developments

13.4 Johnson & Johnson

- 13.4.1 Johnson & Johnson Company Information
- 13.4.2 Johnson & Johnson Hepatitis Drugs Product Portfolios and Specifications
- 13.4.3 Johnson & Johnson Hepatitis Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
- 13.4.4 Johnson & Johnson Main Business Overview
- 13.4.5 Johnson & Johnson Latest Developments

13.5 Merck

13.5.1 Merck Company Information

13.5.2 Merck Hepatitis Drugs Product Portfolios and Specifications

13.5.3 Merck Hepatitis Drugs Sales, Revenue, Price and Gross Margin (2020-2025)

13.5.4 Merck Main Business Overview

13.5.5 Merck Latest Developments

13.6 Novartis

13.6.1 Novartis Company Information

13.6.2 Novartis Hepatitis Drugs Product Portfolios and Specifications

13.6.3 Novartis Hepatitis Drugs Sales, Revenue, Price and Gross Margin (2020-2025)

13.6.4 Novartis Main Business Overview

13.6.5 Novartis Latest Developments

13.7 Vertex Pharmaceuticals

13.7.1 Vertex Pharmaceuticals Company Information

13.7.2 Vertex Pharmaceuticals Hepatitis Drugs Product Portfolios and Specifications

13.7.3 Vertex Pharmaceuticals Hepatitis Drugs Sales, Revenue, Price and Gross Margin (2020-2025)

13.7.4 Vertex Pharmaceuticals Main Business Overview

13.7.5 Vertex Pharmaceuticals Latest Developments

13.8 Abbvie

13.8.1 Abbvie Company Information

13.8.2 Abbvie Hepatitis Drugs Product Portfolios and Specifications

13.8.3 Abbvie Hepatitis Drugs Sales, Revenue, Price and Gross Margin (2020-2025)

13.8.4 Abbvie Main Business Overview

13.8.5 Abbvie Latest Developments

13.9 Achillion Pharmaceuticals

13.9.1 Achillion Pharmaceuticals Company Information

13.9.2 Achillion Pharmaceuticals Hepatitis Drugs Product Portfolios and Specifications

13.9.3 Achillion Pharmaceuticals Hepatitis Drugs Sales, Revenue, Price and Gross Margin (2020-2025)

13.9.4 Achillion Pharmaceuticals Main Business Overview

13.9.5 Achillion Pharmaceuticals Latest Developments

13.10 Bristol-Myers Squibb

13.10.1 Bristol-Myers Squibb Company Information

13.10.2 Bristol-Myers Squibb Hepatitis Drugs Product Portfolios and Specifications

13.10.3 Bristol-Myers Squibb Hepatitis Drugs Sales, Revenue, Price and Gross Margin (2020-2025)

13.10.4 Bristol-Myers Squibb Main Business Overview

13.10.5 Bristol-Myers Squibb Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Hepatitis Drugs Annual Sales CAGR by Geographic Region (2020, 2024 & 2031) & (\$ millions)

Table 2. Hepatitis Drugs Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & (\$ millions)

Table 3. Major Players of VEMLIDY

Table 4. Major Players of EPCLUSA

Table 5. Major Players of SOVALDI

Table 6. Major Players of INCIVEK

Table 7. Major Players of OLYSIO

Table 8. Major Players of VICTRELIS

Table 9. Major Players of VIREAD

Table 10. Major Players of HEPSERA

Table 11. Major Players of BARACLUDE

Table 12. Global Hepatitis Drugs Sales by Type (2020-2025) & (K Units)

Table 13. Global Hepatitis Drugs Sales Market Share by Type (2020-2025)

Table 14. Global Hepatitis Drugs Revenue by Type (2020-2025) & (\$ million)

Table 15. Global Hepatitis Drugs Revenue Market Share by Type (2020-2025)

Table 16. Global Hepatitis Drugs Sale Price by Type (2020-2025) & (USD/Unit)

Table 17. Global Hepatitis Drugs Sale by Application (2020-2025) & (K Units)

Table 18. Global Hepatitis Drugs Sale Market Share by Application (2020-2025)

Table 19. Global Hepatitis Drugs Revenue by Application (2020-2025) & (\$ million)

Table 20. Global Hepatitis Drugs Revenue Market Share by Application (2020-2025)

Table 21. Global Hepatitis Drugs Sale Price by Application (2020-2025) & (USD/Unit)

Table 22. Global Hepatitis Drugs Sales by Company (2020-2025) & (K Units)

Table 23. Global Hepatitis Drugs Sales Market Share by Company (2020-2025)

Table 24. Global Hepatitis Drugs Revenue by Company (2020-2025) & (\$ millions)

Table 25. Global Hepatitis Drugs Revenue Market Share by Company (2020-2025)

Table 26. Global Hepatitis Drugs Sale Price by Company (2020-2025) & (USD/Unit)

Table 27. Key Manufacturers Hepatitis Drugs Producing Area Distribution and Sales Area

Table 28. Players Hepatitis Drugs Products Offered

Table 29. Hepatitis Drugs Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)

Table 30. New Products and Potential Entrants

Table 31. Market M&A Activity & Strategy

Table 32. Global Hepatitis Drugs Sales by Geographic Region (2020-2025) & (K Units)

Table 33. Global Hepatitis Drugs Sales Market Share Geographic Region (2020-2025)

Table 34. Global Hepatitis Drugs Revenue by Geographic Region (2020-2025) & (\$ millions)

Table 35. Global Hepatitis Drugs Revenue Market Share by Geographic Region (2020-2025)

Table 36. Global Hepatitis Drugs Sales by Country/Region (2020-2025) & (K Units)

Table 37. Global Hepatitis Drugs Sales Market Share by Country/Region (2020-2025)

Table 38. Global Hepatitis Drugs Revenue by Country/Region (2020-2025) & (\$ millions)

Table 39. Global Hepatitis Drugs Revenue Market Share by Country/Region (2020-2025)

Table 40. Americas Hepatitis Drugs Sales by Country (2020-2025) & (K Units)

Table 41. Americas Hepatitis Drugs Sales Market Share by Country (2020-2025)

Table 42. Americas Hepatitis Drugs Revenue by Country (2020-2025) & (\$ millions)

Table 43. Americas Hepatitis Drugs Sales by Type (2020-2025) & (K Units)

Table 44. Americas Hepatitis Drugs Sales by Application (2020-2025) & (K Units)

Table 45. APAC Hepatitis Drugs Sales by Region (2020-2025) & (K Units)

Table 46. APAC Hepatitis Drugs Sales Market Share by Region (2020-2025)

Table 47. APAC Hepatitis Drugs Revenue by Region (2020-2025) & (\$ millions)

Table 48. APAC Hepatitis Drugs Sales by Type (2020-2025) & (K Units)

Table 49. APAC Hepatitis Drugs Sales by Application (2020-2025) & (K Units)

Table 50. Europe Hepatitis Drugs Sales by Country (2020-2025) & (K Units)

Table 51. Europe Hepatitis Drugs Revenue by Country (2020-2025) & (\$ millions)

Table 52. Europe Hepatitis Drugs Sales by Type (2020-2025) & (K Units)

Table 53. Europe Hepatitis Drugs Sales by Application (2020-2025) & (K Units)

Table 54. Middle East & Africa Hepatitis Drugs Sales by Country (2020-2025) & (K Units)

Table 55. Middle East & Africa Hepatitis Drugs Revenue Market Share by Country (2020-2025)

Table 56. Middle East & Africa Hepatitis Drugs Sales by Type (2020-2025) & (K Units)

Table 57. Middle East & Africa Hepatitis Drugs Sales by Application (2020-2025) & (K Units)

Table 58. Key Market Drivers & Growth Opportunities of Hepatitis Drugs

Table 59. Key Market Challenges & Risks of Hepatitis Drugs

Table 60. Key Industry Trends of Hepatitis Drugs

Table 61. Hepatitis Drugs Raw Material

Table 62. Key Suppliers of Raw Materials

Table 63. Hepatitis Drugs Distributors List

Table 64. Hepatitis Drugs Customer List

Table 65. Global Hepatitis Drugs Sales Forecast by Region (2026-2031) & (K Units)

Table 66. Global Hepatitis Drugs Revenue Forecast by Region (2026-2031) & (\$ millions)

Table 67. Americas Hepatitis Drugs Sales Forecast by Country (2026-2031) & (K Units)

Table 68. Americas Hepatitis Drugs Annual Revenue Forecast by Country (2026-2031) & (\$ millions)

Table 69. APAC Hepatitis Drugs Sales Forecast by Region (2026-2031) & (K Units)

Table 70. APAC Hepatitis Drugs Annual Revenue Forecast by Region (2026-2031) & (\$ millions)

Table 71. Europe Hepatitis Drugs Sales Forecast by Country (2026-2031) & (K Units)

Table 72. Europe Hepatitis Drugs Revenue Forecast by Country (2026-2031) & (\$ millions)

Table 73. Middle East & Africa Hepatitis Drugs Sales Forecast by Country (2026-2031) & (K Units)

Table 74. Middle East & Africa Hepatitis Drugs Revenue Forecast by Country (2026-2031) & (\$ millions)

Table 75. Global Hepatitis Drugs Sales Forecast by Type (2026-2031) & (K Units)

Table 76. Global Hepatitis Drugs Revenue Forecast by Type (2026-2031) & (\$ millions)

Table 77. Global Hepatitis Drugs Sales Forecast by Application (2026-2031) & (K Units)

Table 78. Global Hepatitis Drugs Revenue Forecast by Application (2026-2031) & (\$ millions)

Table 79. F. Hoffmann-La Roche Basic Information, Hepatitis Drugs Manufacturing Base, Sales Area and Its Competitors

Table 80. F. Hoffmann-La Roche Hepatitis Drugs Product Portfolios and Specifications

Table 81. F. Hoffmann-La Roche Hepatitis Drugs Sales (K Units), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 82. F. Hoffmann-La Roche Main Business

Table 83. F. Hoffmann-La Roche Latest Developments

Table 84. Gilead Sciences Basic Information, Hepatitis Drugs Manufacturing Base, Sales Area and Its Competitors

Table 85. Gilead Sciences Hepatitis Drugs Product Portfolios and Specifications

Table 86. Gilead Sciences Hepatitis Drugs Sales (K Units), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 87. Gilead Sciences Main Business

Table 88. Gilead Sciences Latest Developments

Table 89. GlaxoSmithKline Basic Information, Hepatitis Drugs Manufacturing Base, Sales Area and Its Competitors

Table 90. GlaxoSmithKline Hepatitis Drugs Product Portfolios and Specifications

Table 91. GlaxoSmithKline Hepatitis Drugs Sales (K Units), Revenue (\$ Million), Price

(USD/Unit) and Gross Margin (2020-2025)

Table 92. GlaxoSmithKline Main Business

Table 93. GlaxoSmithKline Latest Developments

Table 94. Johnson & Johnson Basic Information, Hepatitis Drugs Manufacturing Base, Sales Area and Its Competitors

Table 95. Johnson & Johnson Hepatitis Drugs Product Portfolios and Specifications

Table 96. Johnson & Johnson Hepatitis Drugs Sales (K Units), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 97. Johnson & Johnson Main Business

Table 98. Johnson & Johnson Latest Developments

Table 99. Merck Basic Information, Hepatitis Drugs Manufacturing Base, Sales Area and Its Competitors

Table 100. Merck Hepatitis Drugs Product Portfolios and Specifications

Table 101. Merck Hepatitis Drugs Sales (K Units), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 102. Merck Main Business

Table 103. Merck Latest Developments

Table 104. Novartis Basic Information, Hepatitis Drugs Manufacturing Base, Sales Area and Its Competitors

Table 105. Novartis Hepatitis Drugs Product Portfolios and Specifications

Table 106. Novartis Hepatitis Drugs Sales (K Units), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 107. Novartis Main Business

Table 108. Novartis Latest Developments

Table 109. Vertex Pharmaceuticals Basic Information, Hepatitis Drugs Manufacturing Base, Sales Area and Its Competitors

Table 110. Vertex Pharmaceuticals Hepatitis Drugs Product Portfolios and Specifications

Table 111. Vertex Pharmaceuticals Hepatitis Drugs Sales (K Units), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 112. Vertex Pharmaceuticals Main Business

Table 113. Vertex Pharmaceuticals Latest Developments

Table 114. Abbvie Basic Information, Hepatitis Drugs Manufacturing Base, Sales Area and Its Competitors

Table 115. Abbvie Hepatitis Drugs Product Portfolios and Specifications

Table 116. Abbvie Hepatitis Drugs Sales (K Units), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 117. Abbvie Main Business

Table 118. Abbvie Latest Developments

Table 119. Achillion Pharmaceuticals Basic Information, Hepatitis Drugs Manufacturing Base, Sales Area and Its Competitors

Table 120. Achillion Pharmaceuticals Hepatitis Drugs Product Portfolios and Specifications

Table 121. Achillion Pharmaceuticals Hepatitis Drugs Sales (K Units), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 122. Achillion Pharmaceuticals Main Business

Table 123. Achillion Pharmaceuticals Latest Developments

Table 124. Bristol-Myers Squibb Basic Information, Hepatitis Drugs Manufacturing Base, Sales Area and Its Competitors

Table 125. Bristol-Myers Squibb Hepatitis Drugs Product Portfolios and Specifications

Table 126. Bristol-Myers Squibb Hepatitis Drugs Sales (K Units), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 127. Bristol-Myers Squibb Main Business

Table 128. Bristol-Myers Squibb Latest Developments

List Of Figures

LIST OF FIGURES

- Figure 1. Picture of Hepatitis Drugs
- Figure 2. Hepatitis Drugs Report Years Considered
- Figure 3. Research Objectives
- Figure 4. Research Methodology
- Figure 5. Research Process and Data Source
- Figure 6. Global Hepatitis Drugs Sales Growth Rate 2020-2031 (K Units)
- Figure 7. Global Hepatitis Drugs Revenue Growth Rate 2020-2031 (\$ millions)
- Figure 8. Hepatitis Drugs Sales by Geographic Region (2020, 2024 & 2031) & (\$ millions)
- Figure 9. Hepatitis Drugs Sales Market Share by Country/Region (2024)
- Figure 10. Hepatitis Drugs Sales Market Share by Country/Region (2020, 2024 & 2031)
- Figure 11. Product Picture of VEMLIDY
- Figure 12. Product Picture of EPCLUSA
- Figure 13. Product Picture of SOVALDI
- Figure 14. Product Picture of INCIVEK
- Figure 15. Product Picture of OLYSIO
- Figure 16. Product Picture of VICTRELIS
- Figure 17. Product Picture of VIREAD
- Figure 18. Product Picture of HEPSERA
- Figure 19. Product Picture of BARACLUDE
- Figure 20. Global Hepatitis Drugs Sales Market Share by Type in 2025
- Figure 21. Global Hepatitis Drugs Revenue Market Share by Type (2020-2025)
- Figure 22. Hepatitis Drugs Consumed in Hepatitis A
- Figure 23. Global Hepatitis Drugs Market: Hepatitis A (2020-2025) & (K Units)
- Figure 24. Hepatitis Drugs Consumed in Hepatitis B
- Figure 25. Global Hepatitis Drugs Market: Hepatitis B (2020-2025) & (K Units)
- Figure 26. Hepatitis Drugs Consumed in Hepatitis C
- Figure 27. Global Hepatitis Drugs Market: Hepatitis C (2020-2025) & (K Units)
- Figure 28. Hepatitis Drugs Consumed in Hepatitis D
- Figure 29. Global Hepatitis Drugs Market: Hepatitis D (2020-2025) & (K Units)
- Figure 30. Hepatitis Drugs Consumed in Hepatitis E
- Figure 31. Global Hepatitis Drugs Market: Hepatitis E (2020-2025) & (K Units)
- Figure 32. Global Hepatitis Drugs Sale Market Share by Application (2024)
- Figure 33. Global Hepatitis Drugs Revenue Market Share by Application in 2025
- Figure 34. Hepatitis Drugs Sales by Company in 2025 (K Units)

- Figure 35. Global Hepatitis Drugs Sales Market Share by Company in 2025
- Figure 36. Hepatitis Drugs Revenue by Company in 2025 (\$ millions)
- Figure 37. Global Hepatitis Drugs Revenue Market Share by Company in 2025
- Figure 38. Global Hepatitis Drugs Sales Market Share by Geographic Region (2020-2025)
- Figure 39. Global Hepatitis Drugs Revenue Market Share by Geographic Region in 2025
- Figure 40. Americas Hepatitis Drugs Sales 2020-2025 (K Units)
- Figure 41. Americas Hepatitis Drugs Revenue 2020-2025 (\$ millions)
- Figure 42. APAC Hepatitis Drugs Sales 2020-2025 (K Units)
- Figure 43. APAC Hepatitis Drugs Revenue 2020-2025 (\$ millions)
- Figure 44. Europe Hepatitis Drugs Sales 2020-2025 (K Units)
- Figure 45. Europe Hepatitis Drugs Revenue 2020-2025 (\$ millions)
- Figure 46. Middle East & Africa Hepatitis Drugs Sales 2020-2025 (K Units)
- Figure 47. Middle East & Africa Hepatitis Drugs Revenue 2020-2025 (\$ millions)
- Figure 48. Americas Hepatitis Drugs Sales Market Share by Country in 2025
- Figure 49. Americas Hepatitis Drugs Revenue Market Share by Country (2020-2025)
- Figure 50. Americas Hepatitis Drugs Sales Market Share by Type (2020-2025)
- Figure 51. Americas Hepatitis Drugs Sales Market Share by Application (2020-2025)
- Figure 52. United States Hepatitis Drugs Revenue Growth 2020-2025 (\$ millions)
- Figure 53. Canada Hepatitis Drugs Revenue Growth 2020-2025 (\$ millions)
- Figure 54. Mexico Hepatitis Drugs Revenue Growth 2020-2025 (\$ millions)
- Figure 55. Brazil Hepatitis Drugs Revenue Growth 2020-2025 (\$ millions)
- Figure 56. APAC Hepatitis Drugs Sales Market Share by Region in 2025
- Figure 57. APAC Hepatitis Drugs Revenue Market Share by Region (2020-2025)
- Figure 58. APAC Hepatitis Drugs Sales Market Share by Type (2020-2025)
- Figure 59. APAC Hepatitis Drugs Sales Market Share by Application (2020-2025)
- Figure 60. China Hepatitis Drugs Revenue Growth 2020-2025 (\$ millions)
- Figure 61. Japan Hepatitis Drugs Revenue Growth 2020-2025 (\$ millions)
- Figure 62. South Korea Hepatitis Drugs Revenue Growth 2020-2025 (\$ millions)
- Figure 63. Southeast Asia Hepatitis Drugs Revenue Growth 2020-2025 (\$ millions)
- Figure 64. India Hepatitis Drugs Revenue Growth 2020-2025 (\$ millions)
- Figure 65. Australia Hepatitis Drugs Revenue Growth 2020-2025 (\$ millions)
- Figure 66. China Taiwan Hepatitis Drugs Revenue Growth 2020-2025 (\$ millions)
- Figure 67. Europe Hepatitis Drugs Sales Market Share by Country in 2025
- Figure 68. Europe Hepatitis Drugs Revenue Market Share by Country (2020-2025)
- Figure 69. Europe Hepatitis Drugs Sales Market Share by Type (2020-2025)
- Figure 70. Europe Hepatitis Drugs Sales Market Share by Application (2020-2025)
- Figure 71. Germany Hepatitis Drugs Revenue Growth 2020-2025 (\$ millions)

- Figure 72. France Hepatitis Drugs Revenue Growth 2020-2025 (\$ millions)
- Figure 73. UK Hepatitis Drugs Revenue Growth 2020-2025 (\$ millions)
- Figure 74. Italy Hepatitis Drugs Revenue Growth 2020-2025 (\$ millions)
- Figure 75. Russia Hepatitis Drugs Revenue Growth 2020-2025 (\$ millions)
- Figure 76. Middle East & Africa Hepatitis Drugs Sales Market Share by Country (2020-2025)
- Figure 77. Middle East & Africa Hepatitis Drugs Sales Market Share by Type (2020-2025)
- Figure 78. Middle East & Africa Hepatitis Drugs Sales Market Share by Application (2020-2025)
- Figure 79. Egypt Hepatitis Drugs Revenue Growth 2020-2025 (\$ millions)
- Figure 80. South Africa Hepatitis Drugs Revenue Growth 2020-2025 (\$ millions)
- Figure 81. Israel Hepatitis Drugs Revenue Growth 2020-2025 (\$ millions)
- Figure 82. Turkey Hepatitis Drugs Revenue Growth 2020-2025 (\$ millions)
- Figure 83. GCC Countries Hepatitis Drugs Revenue Growth 2020-2025 (\$ millions)
- Figure 84. Manufacturing Cost Structure Analysis of Hepatitis Drugs in 2025
- Figure 85. Manufacturing Process Analysis of Hepatitis Drugs
- Figure 86. Industry Chain Structure of Hepatitis Drugs
- Figure 87. Channels of Distribution
- Figure 88. Global Hepatitis Drugs Sales Market Forecast by Region (2026-2031)
- Figure 89. Global Hepatitis Drugs Revenue Market Share Forecast by Region (2026-2031)
- Figure 90. Global Hepatitis Drugs Sales Market Share Forecast by Type (2026-2031)
- Figure 91. Global Hepatitis Drugs Revenue Market Share Forecast by Type (2026-2031)
- Figure 92. Global Hepatitis Drugs Sales Market Share Forecast by Application (2026-2031)
- Figure 93. Global Hepatitis Drugs Revenue Market Share Forecast by Application (2026-2031)

I would like to order

Product name: Global Hepatitis Drugs Market Growth 2025-2031

Product link: <https://marketpublishers.com/r/GEA9010DB8D4EN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GEA9010DB8D4EN.html>